THE MADISON GROUP

Lobbying for NOVO NORDISK INC. · Pharmaceutical Company

Filing 2nd Quarter - Termination

2nd Quarter (Apr 1 - June 30) 2025 · New Jersey · House · Senate · $60,000.00 income · posted Jul 18, 2025

Lobbying activity 2

Health Issues

Issues and legislation related to (1) Medicare coverage of anti-obesity medications, (2) the 340B drug pricing program, and (3) Medicare Part D coverage of anti-obesity medications, and (4) issues related to compounding and counterfeit drugs.

Medicare/Medicaid

Issues and legislation related to (1) Medicare coverage of anti-obesity medications, (2) the 340B drug pricing program, and (3) Medicare Part D coverage of anti-obesity medications.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.